Friday, October 7th

Abstract Session 1

2:12 – 2:18 PM: "Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response (PSA ≤0.2 ng/mL)." – presented by Dr. Nicolas Sayegh

2:18 – 2:24 PM: "Access to Care and Health Care Quality Metrics in Urban Versus Rural Patients With Advanced Genitourinary Cancers" – presented by Dr. Haoran Li

2:30 – 2:36 PM: "Evaluating the Clinical Significance of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Non-Small Cell Lung Cancer (NSCLC)" – presented by Dr. Mason Alford

2:54 - 3:00 PM: "Trilaciclib Use and Chemotherapy-Induced Myelosuppression Among Patients with ES-SCLC in US Community Oncology Settings" – presented by Dr. Jerome Goldschmidt

3:00 – 3:06 PM: "Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT)." – presented by Dr. Vinay Mathew Thomas

3:06 – 3:12 PM: "Overall survival (OS) after progression on first novel hormonal therapy (NHT) in patients (pts) with metastatic castration-sensitive versus castration-resistant prostate cancer (mCSPC versus mCRPC)." -  presented by Dr. Vinay Mathew Thomas

3:18 – 3:24 PM: "Transcriptomic profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (DN-mCSPC) versus those with mCSPC that have relapsed from prior localized therapy (PLT-mCSPC)" – presented by Dr. Kamal Kant Sahu

3:24 – 3:30 PM: "Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices" – presented by Huan Huang

Abstract Session 2

6:27 – 6:33 PM: "Serial Monitoring of circulating tumor DNA (ctDNA) reliably detects progression and regression in lung cancer patients" – presented by Dr. Ujjwal Karki

6:33 – 6:39 PM: "Genetic mutation profile in HER2 positive lobular breast cancer" – presented by Dr. Suman Gaire

6:45 – 6:51 PM: "Analysis of genetic alterations of DNA repair genes as prognostic marker of survival in cholangiocarcinoma" – presented by Dr. Niraj Neupane

6:51 – 6:57 PM: "Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC" – presented by Dr. Nicolas Sayegh

Saturday, October 8th

10:05 - 10:11 AM: "Tumor genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation (UCS) compared to pure urothelial carcinoma (UC)." – presented by Dr. Nishita Tripathi

10:11 - 10:17 AM: "Tumor genomic landscape in smokers compared to non-smoker patients with locally advanced or metastatic urothelial carcinoma" - presented by Dr. Nishita Tripathi